<DOC>
	<DOCNO>NCT00759837</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics bosutinib safety tolerability bosutinib healthy subject subject liver disease .</brief_summary>
	<brief_title>Study Evaluating The Pharmacokinetics ( PK ) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Inclusion criterion ( study population ) : 1 . Men woman nonchildbearing potential ( WONCBP ) age 18 65 year inclusive screening . WONCBP may include either surgically sterile ( hysterectomy and/or oophorectomy ) postmenopausal 1 year ( folliclestimulating hormone [ FSH ] level great equal 8 mIU/mL ) must negative serum pregnancy test result within 48 hour administration test article . Women surgically sterile must provide documentation procedure operative report ultrasound scan . Sexually active men must agree use medically acceptable form contraception study continue use 12 week test article administration . 2 . Have high probability compliance completion study . Exclusion criterion ( study population ) : 1 . History clinically important cardiovascular disease . 2 . Family history QT prolongation , syncope , seizure , unexplained cardiacrelated death . 3 . Presence history disorder may prevent successful completion study . Other inclusion exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>